Novo Nordisk
United States
1217 articles about Novo Nordisk
-
Data published in the New England Journal of Medicine shows the once-weekly dose of the glucagon-like peptide-1 (GLP-1) analog significantly reduced weight in patients over the course of 68 weeks.
-
Cities Changing Diabetes announces five new programs to fight diabetes and obesity in Philadelphia
1/13/2021
Five innovative community-based programs have been selected to receive preliminary funding to help combat diabetes and obesity in Philadelphia through Cities Changing Diabetes.
-
Novo Nordisk extends COVID-19 Patient Assistance Program, encourages people facing affordability challenges to visit NovoCare.com
1/4/2021
- COVID-19 Patient Assistance Program: Eligible patients can continue to enroll in our Diabetes Patient Assistance Program and receive a free 90-day supply of insulin until June 30, 2021 - My$99Insulin Program: Patients who enrolled in the cash card program in 2020 must reregister to determine if they are eligible to continue participating in 2021
-
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
It’s been a busy day so far for biopharma news and updates. Read on for more.
-
Novo Nordisk Completes Acquisition of Emisphere Technologies for $1.35 Billion
12/8/2020
Emisphere Technologies, Inc. announced the completion of the previously announced transaction whereby Novo Nordisk A/S acquired Emisphere, on a cash-free, debt-free basis, for $1.35 billion.
-
FDA approves Saxenda® for the treatment of obesity in adolescents aged 12-17
12/5/2020
Saxenda® (liraglutide) injection 3 mg becomes the first FDA-approved therapy to treat obesity in adolescents in more than a decade
-
Gilead Sciences and Novo Nordisk presented data from a Phase II proof-of-concept clinical trial of semaglutide in combinations with cilofexor and/or firsocostat in non-alcoholic steatohepatitis.
-
Gilead and Novo Nordisk Present New Data from Proof-of-Concept Trial in NASH
11/15/2020
Results from First Phase 2 Trial Describing a Triple Combination Regimen Targeting NASH Presented at The Liver Meeting Digital Experience
-
Denmark’s Novo Nordisk is acquiring New Jersey-based Emisphere Technologies in a deal worth about $1.8 billion. Novo Nordisk and Emisphere have been partnered since 2007.
-
Semaglutide 2.4 mg injection demonstrated significant weight loss versus placebo when added to intensive behavioural therapy
11/5/2020
Trial participants were adults with obesity or overweight with at least one weight-related co-morbidity and without type 2 diabetes.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for November 3, 2020.
-
Novo Nordisk announced today that it has ended its development of the anti-IL-21 antibody NN9828 in combination with Victoza. The decision was made after analyzing Phase II clinical trial data in patients with Type 1 diabetes.
-
BioSpace Global Roundup, Sept. 24
9/24/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Evotec And Novo Nordisk Form Strategic Alliance to Develop Novel Therapies for Kidney Diseases
8/18/2020
Evotec SE and Novo Nordisk announced a strategic collaboration on the discovery and development of innovative therapeutics for patients with chronic kidney disease.
-
Together the two companies will scour comprehensive medical and molecular data sets of thousands of chronic kidney disease patients to identify and then develop possible drugs.
-
Investigational, once-weekly insulin icodec showed comparable efficacy and safety to once-daily insulin glargine U100 in phase 2 trial
6/15/2020
Novo Nordisk announced results from a phase 2 clinical trial of investigational insulin icodec, a once-weekly basal insulin analog.
-
Sofinnova Partners Announces Sale of Corvidia Therapeutics to Novo Nordisk
6/11/2020
June 11, 2020 13:20 UTC Novo Nordisk acquires Corvidia for $2.1B with an upfront payment of $725M in cash Sofinnova Partners co-founded Corvidia as its sole seed financial investor in 2015 with serial entrepreneur Michael Davidson PARIS--( BUSINESS WIRE )-- Sofinnova Partners , a leading European life sciences venture capital firm based in Paris, London and Milan, announced today the sale of its portfolio company Corvidia Therapeutics to Novo Nordisk, for $2.1 bi
-
Under terms of the deal, Novo Nordisk paid $725 million upfront to Sofinnova for the Waltham, Mass.-based Corvidia, a company focused on the development of transformational therapies for cardio-renal diseases.
-
Novo Nordisk to present new data at the 80th Annual American Diabetes Association Scientific Sessions
6/2/2020
Novo Nordisk announced that new data from 38 abstracts will be featured from the company's approved and investigational diabetes medicines at the upcoming 80 th Annual Scientific Sessions of